Filing Flows

Filing Flows › Companies › Standard Biotools › Cash flow

Standard Biotools cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.2M in Q3 2026 · −$65.6M over twelve months

Operating cash flow−$6.2M
Free cash flow−$6.2M
Cash / net income-0.5×
Cash conversion cycle185 days

Analysis

In Q3 2026, Standard Biotools generated −$6.2M of operating cash flow. That is $16.9M more than in Q3 2025 (−$23.1M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$64.3M; the largest uses were operating cash flow ($64.3M), capital spending ($1.4M), taxes on employees’ shares ($1.1M); besides operations, cash came from other investing ($204M), shares issued ($609K); the cash balance rose by $138M.

Operating cash flow was −$6.2M against net income of $13.5M — -0.5× profit, less cash than reported earnings, worth checking against working capital. The largest differences: accrued liabilities +$8.4M, payables −$6.0M, stock-based pay +$3.7M.

Its cash conversion cycle was 185 days (receivables 68 + inventory 187 − payables 70).

Free cash flow

Standard Biotools: free cash flow by quarterStandard Biotools: free cash flow by quarter−$17.4MQ4 2024−$35.3MQ1 2025−$22.6MQ2 2025−$23.1MQ3 2025−$1.7MQ4 2025−$47.2MQ1 2026−$10.7MQ2 2026−$6.2MQ3 2026
Operating cash flow less capital spending.
Standard Biotools: operating cash flow against capital spendingStandard Biotools: operating cash flow against capital spendingOperating cash flowCapital spending−$14.1M$3.4MQ4 2024−$30.3M$5.1MQ1 2025−$20.7M$1.9MQ2 2025−$22.2M$886KQ3 2025−$1.2M$476KQ4 2025−$46.6M$570KQ1 2026−$10.3M$344KQ2 2026−$6.2M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$6.2M, Capital spending $0.

Capital allocation, year by year

Standard Biotools: where the cash came from (up) and went (down), by fiscal yearStandard Biotools: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$44.1MFY2021: Net borrowing $16.8MFY2021: Shares issued $209KFY2021: Capital spending −$13.3M$17.0MFY2021FY2022: Operating cash flow −$89.4MFY2022: Net borrowing −$6.8MFY2022: Shares issued $225MFY2022: Capital spending −$3.8MFY2022: Buybacks −$563K$225MFY2022FY2023: Operating cash flow −$43.3MFY2023: Net borrowing −$2.1MFY2023: Shares issued $104KFY2023: Capital spending −$2.8MFY2023: Buybacks −$5.4M$104KFY2023FY2024: Operating cash flow −$143MFY2024: Net borrowing −$63.2MFY2024: Shares issued $1.2MFY2024: Capital spending −$8.4MFY2024: Acquisitions −$1.4MFY2024: Buybacks −$40.5M$1.2MFY2024FY2025: Operating cash flow −$74.3MFY2025: Shares issued $531KFY2025: Capital spending −$8.3M$531KFY2025
Over these 5 years operating cash flow totalled −$395M; the largest uses were operating cash flow ($395M) and net borrowing ($72.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$461M
Debtnone
Net cash$461M
Cash runway7.0 years

Standard Biotools is burning cash: its operations consume cash, a free cash flow of −$65.6M a year at the current rate against $461M of cash and investments: a runway of about 7.0 years before any new financing.

Where the cash came from and went

Standard Biotools: sources (+) and uses (−) of cash, Q3 2026Standard Biotools: sources (+) and uses (−) of cash, Q3 2026Asset & business sales$22.5MOther investing−$17.7MOperating cash flow−$6.2MCash drawn (+) / kept (−)$2.6MExchange rates−$627KTaxes on employees’ shares−$598K
Standard Biotools: sources (+) and uses (−) of cash, TTM to Q3 2026Standard Biotools: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$204MCash drawn (+) / kept (−)−$138MOperating cash flow−$64.3MCapital spending−$1.4MTaxes on employees’ shares−$1.1MShares issued$609KOther financing$335KExchange rates−$318K

From profit to cash

Standard Biotools: net income to operating cash flow, Q3 2026Standard Biotools: net income to operating cash flow, Q3 2026Net income$13.5MDepreciation & amortization$1.2MStock-based pay$3.7MReceivables$2.7MInventory−$334KPayables−$6.0MAccrued liabilities$8.4MDeferred revenue−$333KPrepaid and other assets$1.8MOther liabilities$15KOperating cash flow−$6.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20266818770185
Q2 20267317084160
Q1 20266417661179
Q4 20255216845176
Q3 20256622764229
Q2 202510527178298
Q1 202511230883338
Q4 20249321755255

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$6.2M———$2.6M−$6.2M
Q2 2026−$10.3M−$344K——−$4.3M−$10.7M
Q1 2026−$46.6M−$570K—$78K−$145M−$47.2M
Q4 2025−$1.2M−$476K—$531K$8.7M−$1.7M
Q3 2025−$22.2M−$886K——$29.2M−$23.1M
Q2 2025−$20.7M−$1.9M——−$7.7M−$22.6M
Q1 2025−$30.3M−$5.1M——$15.3M−$35.3M
Q4 2024−$14.1M−$3.4M−$55.0M$32K$43.1M−$17.4M

Standard Biotools: income statement and cash flow

Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%. The chart follows the revenue to costs, profit and cash.

Standard Biotools: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.